XML 66 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies - Additional Information (Details)
 3 Months Ended 12 Months Ended
Dec. 29, 2023
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
segment
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Aug. 31, 2023
Aug. 30, 2023
Accounting Policies [Line Items]              
Accumulated deficit     $ (2,961,684,000) $ (2,378,488,000)      
Net cash used in operating activities     (366,757,000) (337,509,000) $ (274,419,000)    
Additional revenue interests, second payment $ 100,000,000            
Other than temporary impairment losses     0 0 0    
Revenue   $ 139,000 622,000 240,000 934,000    
Operating expenses     362,872,000 351,538,000 331,214,000    
Assets     504,452,000 362,356,000      
Liabilities     $ 1,090,389,000 812,176,000      
Sale of stock, additional purchase option 10,000,000            
Number of operating segments | segment     1        
Number of reportable segments | segment     1        
Revenue Interest Purchase Agreement              
Accounting Policies [Line Items]              
Gross purchase price 200,000,000            
GlobeImmune, Inc.              
Accounting Policies [Line Items]              
Revenue     $ 0 0 0    
Interest rate with related party     5.00%        
Advances to support operations     $ 0 0      
Operating expenses     300,000 500,000 $ 700,000    
Assets     1,400,000 1,400,000      
Liabilities     0 $ 0      
GlobeImmune, Inc. | Advances To Related Party | Affiliated Entity              
Accounting Policies [Line Items]              
Advances to related party     $ 6,000,000        
GlobeImmune, Inc.              
Accounting Policies [Line Items]              
Percentage of ownership interest by parent     69.10% 69.10% 69.10%    
NANTibody, LLC              
Accounting Policies [Line Items]              
Percentage of ownership interest by parent     100.00% 60.00% 60.00% 100.00% 60.00%
February 2023 Shelf Registration Statement              
Accounting Policies [Line Items]              
Available for future stock issuance     $ 565,600,000        
Stock Purchase and Option Agreement              
Accounting Policies [Line Items]              
Sale of stock, additional purchase option $ 10,000,000            
ATM Offering Program              
Accounting Policies [Line Items]              
Available for future stock issuance     208,800,000        
License Agreement              
Accounting Policies [Line Items]              
Revenue     $ 0